Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PLUS THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for PLUS THERAPEUTICS, INC.

PSTV

PLUS THERAPEUTICS, INC.

About PLUS THERAPEUTICS, INC.

Plus Therapeutics, Inc. develops targeted radiotherapeutics and medical devices for central nervous system and solid organ cancers. Its core platform delivers high-dose radiation directly to tumors, aiming to improve safety and efficacy over traditional therapies. The company’s key products include REYOBIQ and CNSide diagnostics, targeting brain, leptomeningeal, and pediatric cancers, with a focus on innovative, minimally invasive treatments and companion diagnostic tools.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from PLUS THERAPEUTICS, INC.

1
1
PLUS THERAPEUTICS, INC. Plus Therapeutics Reports Q1 2026 Financial Results with Improved Net Loss

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
PLUS THERAPEUTICS, INC. Plus Therapeutics Reports $22.4 Million Net Loss for 2025, Accumulated Deficit Reaches $515.9 Million

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
PLUS THERAPEUTICS, INC. Plus Therapeutics Reports Q3 2025 Financial Results and Strategic Developments

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
PLUS THERAPEUTICS, INC. Plus Therapeutics Reports Q2 2025 Financial Results with $5.2M Net Income

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
PLUS THERAPEUTICS, INC. Plus Therapeutics Reports Increased Net Loss of $17.4 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
PLUS THERAPEUTICS, INC. Plus Therapeutics Reports $12.98 Million Net Loss for 2024, Highlights Key Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
PLUS THERAPEUTICS, INC. Plus Therapeutics Reports Revenue Growth, Net Loss, and Cash Flow Concerns in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments